GeneType Multi-Test Approved for Commercial Release
Filed with ASX · · 3 pages · English
Melbourne, Australia, 21 February 2022:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease th is delighted to announce that on the 17 February 2022 the Company’s laboratory in Fitzroy, Melbourne has received simultaneous NATA accreditation and US Centers for Medicare and Medicaid Services (CMS) CLI
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Quarterly Activities Report & Appendix 4C
- Momentum Building with Cash Receipts up 112% for Q2 FY22
- GTG delivers material increase in cash receipts
- Presentation to H.C. Wainwright Investment Conference
- Genetic Technologies FY21 Full Year Results
Later from Genetic Technologies
- US Patent Office Grants Patent for COVID-19 Risk Test
- Half Year Report and Accounts
- Genetic Technologies 1H FY22 results
- Acquisition of Global Direct to Consumer Ecommerce Business
- Transformational Pathway to US Payer System
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies